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Programmed cell death ligand-1 (PD-L1) expression may predict the response to both
programmed cell death-1 and PD-L1 inhibitors in lung cancer. However, the extent of
intratumoral heterogeneity of PD-L1 expression, which may cause false negative results,
is largely unexplored. We aimed to assess the intratumoral heterogeneity of PD-L1
expression in surgically resected lung cancer specimens by applying a novel method of
tissue microarray, namely Spiral Arrays, which enables us to observe the heterogeneity in
spiral-shaped tissue cores. Adenocarcinoma and squamous cell carcinoma specimens
were obtained from consecutive patients with lung cancer who had undergone surgical
resection at Nagasaki University Hospital (Nagasaki, Japan) since 2009. Small cell lung
cancer and large cell carcinoma specimens were selected from patients in the same
archive who had undergone resection since 1998. Spiral Arrays were constructed of spi-
ral-shaped cores, prepared from representative blocks of each case, which were sub-
jected to immunohistochemistry using an anti-PD-L1 antibody. Each core was divided into
8 segments and each segment was classified as either PD-L1-positive or PD-L1-negative
using thresholds of 1.0%, 5.0%, 10.0%, and 50.0%, respectively. In total, 138 specimens
were selected, including 60 adenocarcinomas, 59 squamous cell carcinomas, 12 small
cell lung cancers, and 7 large cell carcinomas. The majority of specimens with PD-L1-pos-
itive segments exhibited heterogeneous expression (i.e., had a mixture of PD-L1-positive
and PD-L1-negative segments within a core) irrespective of the threshold (1.0%, 66.7%;
5.0%, 74.4%; 10.0%, 75.8%; and 50.0%, 85.7%]. Large variations in the ratios of PD-L1-
positive segments were observed. At least 50.0% of the segments within a core were neg-
ative in no fewer than 50.0% (range, 50.0–76.0%) of cases with heterogeneous PD-L1
expression. In conclusion, intratumoral heterogeneity of PD-L1 expression was frequently
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observed in cases of lung cancer. Thus, multiple tumor biopsy specimens may be needed
to accurately determine the PD-L1 expression status.
Introduction
Lung cancer is the leading cause of cancer-related mortality. The 5-year relative survival rate is
10.0–15.0% worldwide [1] and is currently 29.7% in Japan [2]. Although, during the last few
decades, patients with lung cancer have been treated with a variety of tailored therapeutic strat-
egies (e.g., according to histological type or gene expression profiles) [3, 4], survival still
remains poor. Recently, immunotherapy targeting immune checkpoint molecules, especially
programmed cell death-1 and programmed cell death ligand-1 (PD-L1), have been approved
by the United States Food and Drug Administration for the treatment of patients with
advanced non-small cell lung cancer (NSCLC), and are changing the paradigm for therapy in
lung cancer [5–7]. At the same time, the assessment of PD-L1 expression using immunohis-
tochemistry (IHC) has become important as a biomarker for predicting response to these ther-
apies [8, 9]. However, previous studies have reported a broad range of PD-L1 expression in
NSCLC, ranging from 7.4% to 72.7% of cases [10, 11]. Furthermore, a therapeutic response
has been observed not only in patients classified as PD-L1-positive from IHC, but also in some
patients classified as PD-L1-negative from IHC, indicating the potential for insufficient sam-
pling to have occurred from the PD-L1-positive region. Some studies have reported the pres-
ence of intratumoral heterogeneity of PD-L1 expression in lung cancer. However, the rate and
characteristics of the heterogeneity remain largely unexplored [12–15].
In the present study, we aimed to assess the intratumoral heterogeneity of PD-L1 expression
in surgically resected lung cancer specimens by employing a unique tissue microarray tech-




The study protocol was approved by the Ethical Review Board Committee (approval number:
16072526) of Nagasaki University (Nagasaki, Japan) on July 26, 2016. Informed consent was
obtained from each patient at the time of surgery.
Tissue specimens
Adenocarcinoma and squamous cell carcinoma specimens were prospectively obtained from
consecutive patients with lung cancer who had undergone surgical resection at Nagasaki Uni-
versity Hospital (Nagasaki, Japan) since 2009. Small cell lung cancer and large cell carcinoma
specimens were also selected from patients in our institutional archive, but who had under-
gone surgical resection since 1998, because of the low number of cases due to the infrequency
of these histological types. Pathological reports were reviewed and patients with only one of
these histological components were included. Hematoxylin and eosin (H&E)-stained slides
were also reviewed, and patients with insufficient numbers of malignant cells to construct the
Spiral Arrays were excluded. Patients lacking sufficient formalin-fixed, paraffin-embedded tis-
sue were also excluded.
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Spiral Array construction
Spiral Arrays were constructed as described previously (Fig 1) [17]. Briefly, single blocks of tis-
sue with the most representative tumor histology and of sufficient quantity was selected from
each case. The corresponding H&E-stained slide was digitally scanned using a ScanScope1
Aperio CS2 slide scanner (Leica Microsystems, Melbourne, Australia). The scanned whole-
slide image of each H&E-stained slide was reviewed to select and mark two continuous straight
regions of interest (X and Y axes) prior to constructing the Spiral Arrays. Two 120.0-μm-thick
sections were subsequently cut from each block and arranged together on the Spiral Array
Constructor (Sakura Finetek Japan Co., Ltd., Tokyo, Japan) as the X or Y axis on each section
was aligned in the same direction. The aligned sections were rolled together into a cylindrical
form and cut along the line reflecting the X and Y axes. One of the separated reels was embed-
ded vertically into a recipient block to construct the Spiral Arrays. Finally, 4.0-μm-thick sec-
tions were prepared from the Spiral Array blocks for further histopathological evaluation
using H&E staining and IHC.
Antibody selection and immunohistochemistry
Well-characterized anti-PD-L1 (clone 28–8; Abcam, Cambridge, MA, USA) and anti-cluster
of differentiation 68 (CD68) (clone KP1; DAKO, Glostrup, Denmark) antibodies were
selected. IHC was performed using an automated staining system (Leica Bond III; Leica
Microsystems). The antibody dilutions were optimized to 1:100 for anti-PD-L1 and 1:400 for
anti-CD68. The slides were dewaxed and rehydrated using distilled water, and were subse-
quently processed for PD-L1 (heat-induced antigen retrieval at pH 9.0) or CD68 (proteolytic
treatment). After incubation with the primary antibodies (anti-PD-L1, 30 minutes; anti-CD68,
15 minutes), the tissue sections were rinsed, and the sections for PD-L1 staining were further
incubated with EnVision FLEX+ Rabbit LINKER (DAKO) and EnVision+ HRP Labelled
Fig 1. Spiral Array construction. A representative block was selected from each case, and two continuous
straight regions of interest (X and Y axes) were selected and marked by reviewing hematoxylin and eosin-
stained slides. Two 120.0-μm-thick sections were sliced from each block and aligned with the X and Y axes.
The two sections were rolled together into a cylindrical form and cut along the line reflecting the X and Y axes.
Spiral Array cores were embedded vertically into a recipient block. Four-μm-thick sections were prepared
from the Spiral Array blocks for further histopathological evaluation.
https://doi.org/10.1371/journal.pone.0186192.g001
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Polymer (DAKO). The sections for CD68 staining were incubated with the Bond Polymer
Refine Detection Kit (Leica Microsystems). Staining was visualized using diaminobenzidine,
and counterstaining was performed using hematoxylin. Formalin-fixed, paraffin-embedded
tissue blocks of human placenta and tonsil were prepared as positive controls. The stained
slides were scanned as whole-slide images using a ScanScope1 Aperio CS2 slide scanner
(Leica Microsystems).
PD-L1 immunohistochemistry scoring on the Spiral Array
PD-L1 expression was only evaluated in tumor cells. We attempted to exclude intratumoral
immune cells, such as macrophages and lymphocytes. PD-L1 positivity was defined as any
tumor cell that expressed PD-L1 on the cell membrane at any intensity. The tumor cells’
PD-L1 positivity was scored using four different positivity thresholds (1.0%,5.0%,
10.0%, and50.0%) in any tumor that included a minimum of 100 tumor cells.
To evaluate tissue heterogeneity, each Spiral Array core was divided into 8 segments as
shown in Fig 2, and positive or negative PD-L1 expression was scored for each segment. Scor-
ing was performed by two or three independent observers. Segments with interobserver dis-
agreement were subsequently evaluated at a meeting between the independent observers and a
pulmonary expert, and the final classification was selected after a consensus was reached.
Cases with both positive and negative segments within the Spiral Array core were defined as
having heterogeneous PD-L1 expression, while cases with identical results for all 8 segments
(positive/negative) were defined as having homogeneous PD-L1 expression.
Fig 2. Schematic of the 8 segments of a Spiral Array core. Each core was divided into 8 segments for the
scoring of PD-L1 expression.
https://doi.org/10.1371/journal.pone.0186192.g002
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Comparison between Spiral Arrays and whole tissue sections
Six cases were randomly selected from those with positive PD-L1 staining in the Spiral Array.
The staining heterogeneity was compared between the Spiral Array core and the whole tissue
section in each case.
Statistical analyses
The patients’ characteristics at diagnosis were presented as the frequency and percentage for
categorical data, and as the median and interquartile range for continuous data. Interobserver
agreement for PD-L1 IHC scoring was assessed using the kappa statistic for all possible pairs
among the three observers. An average kappa statistic was also calculated for each value [19,
20].
Descriptive and comparative analyses were performed using Microsoft Excel 2010 (Micro-
soft Corporation, Redmond, WA, USA) and JMP software for the patients’ characteristics
(version 11; SAS Institute Inc., Cary, NC, USA). The kappa statistics were calculated using
Microsoft Excel 2010 (Microsoft Corporation) and Easy R software (Saitama Medical Center,
Jichi Medical University, Saitama, Japan) [21], a graphical user interface for R (The R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
The patients’ clinicopathological characteristics are shown in Table 1. Among the 138 cases of
lung cancer, we identified 60 cases of adenocarcinoma, 59 cases of squamous cell carcinoma,
12 cases of small cell lung cancer, and 7 cases of large cell carcinoma. The majority of patients
were male (73.9% vs. 26.1%), and the median age was 70 (range, 41–90) years. The majority of
patients were current or former smokers (18.1% and 57.3%, respectively). The median smok-
ing index was 900 (range, 0–3,220). Almost all of the patients had Stage I, II, or IIIA disease
(59.4%, 22.5%, and 13.8%, respectively).
PD-L1 expression and heterogeneity
Representative images of PD-L1 expression for each criterion are shown in Fig 3A–3E. Repre-
sentative cores with and without heterogeneous PD-L1 expression are shown in Fig 4A and
4B. The distributions of cases with negative, heterogeneous, and homogeneous PD-L1 expres-
sion are shown in Fig 5A and 5B. The threshold-specific number of cases with1 PD-L1-posi-
tive segment was 42 (30.4%), 39 (28.3%), 33 (23.9%), and 21 (15.2%) for the 1.0%, 5.0%, 10.0%,
and 50.0% thresholds, respectively. The majority of cases had heterogeneous PD-L1 expression
irrespective of the threshold (1.0%: 66.7% [n = 28], 5.0%: 74.4% [n = 29], 10.0%: 75.8%
[n = 25], and 50.0%: 85.7% [n = 18]) (Fig 5A). When cases were categorized according to their
histological type, PD-L1-positive segments were observed in 6.7–13.3% of adenocarcinomas,
25.4–49.2% of squamous cell carcinomas,25.0% of small cell lung cancers, and 28.6% of
large cell carcinomas, depending on the threshold that was used (Fig 5B). At least 50.0% of the
8 segments within the cores were negative for PD-L1 expression in the majority of cases with
heterogeneous PD-L1 expression irrespective of the threshold (range, 50.0–76.0%), although
the ratio of PD-L1-positive segments varied considerably among the cases (Fig 6). The hetero-
geneous and homogenous staining patterns of PD-L1 expression were identical between the
Spiral Arrays and whole tissue sections in all 6 randomly selected cases (Fig 7A–7D and S1
Fig). The heterogeneous expression pattern of PD-L1 on the Spiral Arrays was comparable to
that of the original whole tissue sections (Fig 7A–7D).
Intratumoral heterogeneity of PD-L1 in lung cancer
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Interobserver agreement of PD-L1 expression scores
The interobserver agreement for PD-L1 IHC scoring among the three observers is shown in
Table 2. In total, 917 segments were scored by the three observers. The number of segments in
agreement between the three observers (i.e., positive vs. negative) for each threshold (1.0%,
5.0%, 10.0%, and 50.0%) were 814, 824, 850, and 869, respectively. The average kappa statistics
were 0.76, 0.75, 0.78, and 0.79 for the 1.0%, 5.0%, 10.0%, and 50.0% thresholds, respectively.
Discussion
In the present study, using a newly developed tissue microarray method, namely Spiral Arrays,
we revealed that intratumoral heterogeneity of PD-L1 expression was common in lung cancer.
In past studies, the intratumoral heterogeneity of PD-L1 expression has been reported in solid
tumors, including lung cancer, breast cancer, melanoma, and renal cell carcinoma [10, 12–14,
22–29]. However, the majority of studies have evaluated the intratumoral heterogeneity
Table 1. Patient characteristics.




Age (years), median (range) 70 (41–90)





Smoking index, median (range) 900 (0–3,220)
Histology, n (%)
Adenocarcinoma 60 (43.5)
Squamous cell carcinoma 59 (42.7)
Small cell lung cancer 12 (8.7)







Tumor size (mm), median (range) 25.0 (9.0–100.0)
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between primary and metastatic sites [14, 26], and only a few studies have evaluated the intra-
tumoral heterogeneity within tumors. McLaughlin et al. [12], for instance, have recently evalu-
ated the intratumoral heterogeneity within surgically resected NSCLC tumor specimens using
IHC and quantitative fluorescence, and have reported the presence of intratumoral heteroge-
neity of PD-L1 expression. Furthermore, an autopsy case report revealed that PD-L1 and asso-
ciated immunogenetic profiles differed according to metastatic site in the same patient [15].
Fig 3. Representative images of PD-L1 expression. (A) <1.0%, (B) 1.0–4.9%, (C) 5.0–9.9%, (D) 10.0–
49.9%, and (E)50.0% PD-L1-positive cells (magnification, 200×).
https://doi.org/10.1371/journal.pone.0186192.g003
Fig 4. Representative images of the heterogeneous and homogeneous expression of PD-L1. (A)
Heterogeneous and (B) homogeneous expression of PD-L1 (magnification, 150×).
https://doi.org/10.1371/journal.pone.0186192.g004
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To our knowledge, this is the first study to evaluate the intratumoral heterogeneity of lung
cancer using a segmental approach with several thresholds. We used a Spiral Array technique
with 8 segmented cores to evaluate intratumoral heterogeneity. Specimens with both
PD-L1-positive and PD-L1-negative segments within the cores were defined as having hetero-
geneous PD-L1 expression. Our findings suggest that PD-L1 frequently exhibits heterogeneity
in its expression (Fig 5A). Interestingly,50.0% of the 8 segments within the cores were nega-
tive for PD-L1 expression in no fewer than 50.0% of the cases with heterogeneous PD-L1
expression (range, 50.0–76.0%). Thus, cases with heterogeneous PD-L1 expression are more
likely to return a false negative result during an assessment that uses small biopsy specimens.
Recently, Ilie et al. [14] and Kitazono et al. [26] compared PD-L1 expression in surgically
resected specimens and matched small biopsies from patients with NSCLC. A large difference
in the discordant rate (48.0% vs. 7.6%) was observed between the two reports. Our findings
were comparable to those of Ilie et al. [14], suggesting that the apparent PD-L1 status in diag-
nostic biopsies may not reflect that in resected specimens in many cases. Lung cancer is often
only clinically detected in its advanced stages, and a small biopsy is a common primary method
Fig 5. Distributions of cases with negative, heterogeneous, and homogeneous PD-L1 expression. (A)
Distributions of all 138 cases and (B) distributions according to histological type.
https://doi.org/10.1371/journal.pone.0186192.g005
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for diagnosis and molecular testing. PD-L1 expression is also usually assessed in the clinic
using small biopsy specimens [30, 31]. Thus, a higher number of biopsy specimens should be
obtained from a single site. However, few studies have evaluated the association between the
number of biopsy specimens and biomarker sensitivity.
Interobserver agreement regarding PD-L1 expression scores slightly varies according to the
thresholds. However, all the thresholds produced good [32]. Disagreement among the three
observers may be related to the inadvertent inclusion of immune cells that stain positive for
Fig 6. Distributions of cases with heterogeneous PD-L1 expression and varying numbers of
PD-L1-positive segments. The left side of the black line indicates the proportions of cases where negative
segments account for50.0% of the total number of segments within the cores and the right side of the black
line indicates the proportions of cases where positive segments account for >50.0% of the total number of
segments within the cores. At any of the thresholds,50.0% of the total number of segments within the cores
were negative in no fewer than 50.0% (range, 50.0–76.0%) of cases with heterogeneous PD-L1 expression.
https://doi.org/10.1371/journal.pone.0186192.g006
Fig 7. Representative images of PD-L1 expression in a case with heterogeneous PD-L1 expression.
(A) The whole section (magnification, 3×), (B) the corresponding Spiral Array core (magnification, 15×), (C)
magnified images from the regions delineated by the dotted lines in A (left) and B (right) (magnification, 200×),
and (D) magnified images from the regions delineated by the solid lines in A (left) and B (right) (magnification,
200×). Images of the other 5 cases are shown in S1 Fig.
https://doi.org/10.1371/journal.pone.0186192.g007
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PD-L1 (e.g., dendritic cells or macrophages that infiltrate the tumor nests). Although CD68
IHC was performed to eliminate macrophages, in some instances, it was difficult to differenti-
ate between tumor cells and macrophages (Fig 8A–8C). Thus, we propose that a minimum of
two pathologists perform the PD-L1 scoring for each case, and also that CD68 IHC should be
used for the assessment of PD-L1 expression in the clinic.
This study has several limitations. First, we retrospectively evaluated surgically resected
specimens, and PD-L1 expression is usually assessed in the clinic using small biopsy speci-
mens. Second, we used only one antibody (clone 28–8) against PD-L1 to limit the confusion
caused by differences in antigen recognition between different clones. Clone 28–8 has been
characterized by several investigators and is used in clinical trials of lung cancer [28, 33–37].
Finally, data were obtained using only the Spiral Array technique, since concordance between
the findings from Spiral Arrays and whole tissue sections has been established in a previous
study [17].
Conclusions
Intratumoral heterogeneity of PD-L1 expression was frequently observed in cases of lung can-
cer. Thus, our findings suggest that a relatively large number of tumor biopsy specimens may
be needed to accurately determine PD-L1 expression status.
Supporting information
S1 Fig. Six randomly selected cases with heterogeneous staining between Spiral Arrays and
whole tissue sections. Identical staining patterns were observed in all 6 cases.
(PDF)
Table 2. The kappa statistics for the PD-L1 immunohistochemistry scores for segments (n = 917).
Threshold
1% 5% 10% 50%
Observer1 Observer2 0.72 0.70 0.76 0.80
Observer2 Observer3 0.77 0.72 0.75 0.73
Observer1 Observer3 0.79 0.82 0.83 0.84
Average 0.76 0.75 0.78 0.79
https://doi.org/10.1371/journal.pone.0186192.t002
Fig 8. Representative images of a region containing macrophages that resemble tumor cells.
Immunohistochemical analysis of (A) PD-L1 and (B) CD68 expression, and (C) hematoxylin and eosin
staining (magnification, 200×).
https://doi.org/10.1371/journal.pone.0186192.g008
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